335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22708 | *Must have received at least one NAAD(enzalutamide or abiraterone). *1 or 2 prior treatment with taxane *Progressive disease |
Carlos Artigas Guix | prostate | Endocyte | VISION | Trial closed | VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | carlos.artigas@hubruxelles.be | 3 | 3 | |
| 22694 | "3rd line metastatic " | Thierry Gil | Gastrointestinal stromal tumors (GIST) | Blueprint Medicines Corporation | Voyager | Trial closed | An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22752 | Triple negative. Metastatic. 1st Line | Andrea Gombos | Breast | Roche | WO29522 | Trial closed | A Phase III, MULTICENTER, RANDOMIZED, placebo-controlled Study OF MPDL3280A (Anti-PD-L1 Antibody) IN COMBINATION WITH NAB-PACLITAXEL COMPARED with placebo with NAB-PACLITAXEL for PATIENTS WITH previously UNtreated metastatic TRIPLE-NEGATIVE BREAST CANCER | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22755 | Absence of metastasis | Spyridon Sideris | Ureters - bladder - urethra | Roche | WO29636 | Trial closed | WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti?Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 22686 | HER2+. Early breast cancer | Evandro De Azambuja | Breast | Roche | WO40324 | Trial closed for recruitment | A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in combination with chemotherapy in patients with HER2-positive early breast cancer | 3 | 3 | ||
| 29649 | Nieves Martinez Chanza | Colon | Exelixis | XL092-002 - Stellar 002 | Trial open for recruitment | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | nieves.martinez-chanza@hubruxelles.be | 1/1b | 1 | ||
| 22725 | RECIST 1.1 | Yassine Lalami | Thyroïd | Exelixis | XL184-311 | Trial closed | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy | yassine.lalami@hubruxelles.be | 3 | 3 | |
| 22834 | Intermediate or poor risk metastatic clear cell renal cell carcinoma in 1st line treatment. | Nieves Martinez Chanza | Multiple | Exelixis | XL184-313 | Trial closed for recruitment | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
| 29752 | Christiane Jungels | Xenothera | XT 23-01 - FIPO23 | Trial open for recruitment | A Phase I/II Open Label, Multiple Dose, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetic and Efficacy of the glyco-humanized polyclonal antibody XON7 in patients with Advanced Solid Tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |||
| 22731 | Triple-negative breast cancer | Philippe Aftimos | Breast | Zenith Epigenetics Ltd. | ZEN003694-004 | Trial closed | A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22611 | *HER2+ invasive carcinoma of the breast *progressive disease with at least 2 non-bone 'target' metastatic lesions *biopsy of a metastatic site before inclusion |
Patrick Flamen | Breast | Institut Jules Bordet | ZEPHIR | Trial closed for recruitment | A phase II prospective imaging study evaluating the utility of pretreatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy : T-DM1 | patrick.flamen@hubruxelles.be | 2 | 2 | |
| 29237 | Michail Ignatiadis | Breast | GSK | ZEST | Trial closed for recruitment | A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
| 22739 | *Single indeterminate renal mass <=7cm *scheduled nephrectomy within 90 days from planned Zr-TLX250 administration |
Carlos Artigas Guix | Kidney | Telix International Pty Ltd | ZIRCON | Trial closed | A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON Study) | carlos.artigas@hubruxelles.be | 3 | 3 |